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Nimodipine is a widely used medication for treating delayed cerebral ischemia (DCI) after subarachnoid hemorrhage. When
administrated orally or intravenously, systemic hypotension is an undesirable side effect. Intracranial subarachnoid delivery of
nimodipine during aneurysm clipping may be more efficient way of preventing vasospasm and DCI due to higher concentration of
nimodipine in cerebrospinal fluid (CSF).The risk of systemic hypotensionmay also be decreasedwith intracranial delivery.We used
animal models to evaluate the feasibility of surgically implanting a silica-based nimodipine releasing implant into the subarachnoid
space through a frontotemporal craniotomy. Concentrations of released nimodipine were measured from plasma samples and CSF
samples. Implant degradation was followed using CT imaging. After completing the recovery period, full histological examination
was performed on the brain and meninges. The in vitro characteristics of the implant were determined. Our results show that the
biodegradable silica-based implant can be used for an intracranial drug delivery systemandnomajor histopathological foreign body
reactions were observed. CT imaging is a feasible method for determining the degradation of silica implants in vivo. The sustained
release profiles of nimodipine in CSF were achieved. Compared to a traditional treatment, higher nimodipine CSF/plasma ratios
can be obtained with the implant.
1. Introduction
Delayed cerebral ischemia (DCI) is a serious complication
of subarachnoid hemorrhage (SAH). Nimodipine is one
of few effective treatments with clinical evidence for this
condition [1, 2]. Knowledge of the pathophysiology of the
DCI and the underlying vasospasm has evolved in recent
years to a complex entity of early brain injury, secondary
injuries, and cortical spreading ischemia, instead of being
pure intracranial vessel spasm [3–7]. The consequence of a
diligent research for understanding the mechanism of SAH
has led to the development of new tentative therapies to treat
DCI, many showing promising preliminary results [8–11].
Recently, cilostazol was reported to improve outcome among
SAH patients when added to a conventional treatment [12].
The severity of the complications caused by DCI and
relatively ineffective current treatment strategies have led to
the search of new routes to administrate nimodipine for SAH
patients [13]. Intra-arterial, intrathecal, intraventricular, and
intracranial routes have been described [14–18]. By obtaining
higher concentrations of nimodipine in the CSF, it may
be possible to reduce the risk of vasospasm [15]. Higher
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concentrations of nimodipine in the cerebrospinal fluid
(CSF) can also increase other beneficial effects of nimodipine,
for example, neuroprotection for delayed neuronal apop-
tosis and fibrinolysis of microthrombosis [19–22]. In an
experimental SAH rat model, nimodipine inhibited cortical
spreading ischemia (CSI) [22]. These alternative adminis-
tration routes also help in achieving sufficient therapeutic
concentrations in subarachnoid space with lower systemic
nimodipine concentrations, thereby reducing the risk for
systemic hypotension, which may be detrimental for patients
with intracranial vasospasm.
Nimodipine in poly-D,L-lactide coglycolide (PLGA)
implants has been described in the literature [23, 24].
The efficacy of intracranial nimodipine therapy is under
research and the results of the studies have been encouraging
[15, 25, 26]. Other calcium channel blockers incorporated
into PLGA implants have been described and studied as
well, including mibefradil and nicardipine [27–29]. At the
moment, nimodipine is the only calcium channel blocker
that is approved for treating SAH and hypothesized to have
pleiotrophic effects that can improve outcome without the
reduction of vasospasm [15, 19, 21, 27]. Thus that is making
it an interesting candidate for developing new administration
routes where intracranial administration of sustained release
implant or gel seems utilitarian [30].
Calcium channel blockers formulated in a silicate matrix
have not been yet described in the literature. Silica has a
potential to formmicropores where the active drug can bond,
thus forming a sustained drug delivery system (SDDS). Silica
is under active research due to its extensive scale of applica-
tions for drug delivery. Silica-based controlled drug delivery
systems are competent for pure sustained-release systems
but can be functionalized to response changes in pH, redox
potential, temperature, biomolecules, or evenmagnetism and
luminescence [31, 32]. Silica-based SDDS can be formulated
to solid implant as well as gel with different viscosity [33].
Considering the extensive functionalizing possibilities, we
formulated a silica-based sustained drug release nimodipine
implant and tested its feasibility of implantation into the
subarachnoid space and its local histological effects in pigs
and dogs. We also measured concentrations of nimodipine
in plasma and CSF and properties of the new implant and
evaluated the tolerability.
2. Material and Methods
2.1. Preparation of Silica-Based Implants. The silica implants
were prepared from tetraethoxy silane (TEOS 98%, Sigma-
Aldrich, USA), deionized water (Millipore, Milli-Q >
17.5MΩ cm), ethanol (EtOH, Etax AA 99.5%, Altia, Finland),
and hydrochloric acid (HCl, Merck, USA) as catalyst using
the sol-gel method [34]. The molar H
2
O/TEOS ratio was
2 and the molar EtOH/TEOS ratio was 1. After hydrolysis
sols were aged at 60∘C temperature. After ageing of the sols,
the nimodipine (or glucose) was dissolved into the sols. The
pH of the sols was adjusted by sodium hydroxide solution
(NaOH, Merck, USA). The final pH of the sols was 5.5.
Sols were sterile filtered (Whatman, 0.22𝜇m) and cast into
polytetrafluoroethylene molds. The sols were gelled in 6 days
Figure 1: Formulated silica-based nimodipine implants, 10 wt%.
at room temperature (RT). Formed implants were dried in a
desiccator at RT. The initial concentrations of nimodipine in
the sol were 10 weight (wt) % (implant A, implanted to pigs)
and 15wt% (implant B, implanted to dogs) corresponding to
the amount of SiO
2
(Figure 1).
2.2. Dissolution of Monoliths In Vitro. Degradation of silica
matrices wasmeasured in 50mMTRIS (Trisma—preset crys-
tals, Sigma-Aldrich) + 0.1% (wt/wt) sodium dodecyl sulfate
(SDS, Merck) buffered at pH 7.4 (37∘C). SiO
2
concentrations
in the dissolution medium were kept below 30 ppm to ensure
in sink condition (free dissolution of the SiO
2
matrix). If
needed, the whole dissolution medium was changed to the
freshmedium in order to keep SiO
2
concentrations< 30 ppm.
Degradation of silica matrices was also measured via flow-
through dissolution method. In the flow-through dissolution
method, one implant was moved into sample container
with 150mL dissolution medium and dissolution medium
was changed continuously by pumping dissolution medium
through sample container 347 𝜇L/min (c.a. 500mL/day).The
silica concentrations were measured with UV/VIS spec-
trophotometer (V-560, Jasco) analyzing the molybdenum
blue complex absorbance at 𝜆 = 820 nm [35]. Release of
nimodipine from the SiO
2
matrices was analyzed with high
pressure liquid chromatography (HPLC-UV) by CRST in
Turku. The chromatographic separation was obtained on a
Gemini 5𝜇 C18 110A, 150 × 2.0mm (Phenomenex) analytical
HPLC column. The mobile phase consisted of a mixture of
acetonitrile and 15mM hydrogen phosphate buffer (60 : 40
volume/volume).
2.3. Animal Models. Studies were performed using a domes-
tic landrace pig and a Beagle dog model. Both groups
included nine animals in total. The Beagle dogs were bred
by Harlan-Winkelmann GmbH Hundezucht, Germany. The
pigs were purchased from a local farm following strict
health monitoring program. All procedures were made
according to European Community Guidelines for the use
of experimental animals and approved by Finnish National
Animal Experiment Board (licenses ESAVI/2246/2011 and
ESAVI/2643/2012).
Nine eight-week-old male pigs, weighing between 18,6
and 26,1 kg, and nine four-year-oldmale dogs, weighing 10,0–
14,0 kg, were randomly selected for the operation. Board-
certified neurosurgeons were blinded for the content of
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Table 1: Allocation of treatment groups and schedule of the pig study.
Group Procedure Parenchyma implant Animals per group Animal IDs
Sham Sham operation No implant 3 22A, 22B, and 23C
Placebo Placebo implant 25mg glucose × 1 Placebo implant 3 22C, 23A, and 23F
Active Nimodipine implant 5mg × 1 Placebo implant 3 23B, 23D, and 23E
Samples Day 1 Day 4 Day 51 Day 7
Plasma (ear vein) x x
Plasma (vena jugularis) x x x x
Cerebrospinal fluid x x
CT x x2
1Day 6 on animals 22A, 22B, and 22C.
2Only animals 23A and 23D underwent CT-imaging.
Table 2: Allocation of treatment groups and schedule of the dog study.
Group Procedure Parenchyma implant Animals per group Animal IDs
Active 1 Nimodipine implant 8.5mg × 5 (total 42.5mg) NA 3 1, 2, 3
Active 2 Nimodipine implant 8.5mg × 1 NA 3 4, 5, 6
Sham Sham operation NA 3 7, 8, 9
Samples Day 1 Day 5 Day 7 Day 14 Day 21
Plasma (vena jugularis) 1 h, 1.5 h, 2.5 h, 4 h, 6 h, and 22 h (on day 2) x x x x
Cerebrospinal fluid 1 h x x x
CT x x x
NA = not applicable.
the implants in all surgeries. Five implants were determined
to be the number of implants for testing toxicity of the
nimodipine silica implant (Active 1). The group receiving
one implant was considered as a regular treatment group at
expected pharmacological dose and any adverse effects were
not expected (Active 2). Schedule of the study and allocation
to treatment groups are presented in Table 1 for the pigs and
Table 2 for the dogs. Day 1 indicates the operation day.
2.4. Anesthesia and Analgesia. At day 1, pigs and dogs
were sedated, anesthetized, intubated, and connected to a
ventilator for surgery. Pigs were sedated with midazolam
1mg/kg i.m. and xylazine 3mg/kg i.m. and anesthesia was
maintained with propofol infusion 10mg/kg/h i.v. Dogs were
sedated using dexmedetomidine 20𝜇g/kg i.v. and anesthesia
was induced with slow propofol bolus 3mg/kg i.v. and main-
tained with a propofol infusion 9mg/kg/h i.v. Heart rate,
oxygen saturation, and rectal temperature were observed
and recorded throughout the procedure. As a prophylactic
antibiotic, cefuroxime was administered before operation,
250mg i.v. for dogs and 750mg i.v. for pigs. For analge-
sia, Fentanyl was administered to pigs intraoperatively 8–
13 𝜇g/kg i.v. and 3–7 days postoperatively using a 50 𝜇g/h
transdermal patch. For dogs, fentanyl was administered
intraoperatively 3 𝜇g/kg i.v. and 3 days postoperatively using
a 50 𝜇g/h transdermal patch.
Pigs were sedated for blood andCSF sampling withmida-
zolam 1mg/kg i.m. and xylazine 3mg/kg i.m. For CSF, sam-
pling anesthesia was induced with propofol bolus 3mg/kg i.v.
for pigs. Sedation of dogs for CSF sampling was done using
dexmedetomidine 20𝜇g/kg i.v. and a slow propofol bolus
3mg/kg i.v. Sedation or anesthesia was not required for dogs
when only venous blood samples were collected.
Pigs were sedated for CT imaging procedures with
midazolam 1-2mg/kg i.m. and xylazine 3−6mg/kg i.m. and
anesthesia was maintained with propofol 8−15mg/kg/h i.v.
infusion. For the dogs, dexmedetomidine 20𝜇g/kg i.v. was
used for the sedation and anesthesia was induced with slow
propofol bolus 3−5mg/kg i.v. and maintained as needed with
propofol boluses during CT imaging.
2.5. Surgery. During the surgical procedures, the heart rate,
the rectal temperature, and the oxygen saturation were
recorded in every fifteen minutes. Similar surgical approach
was used for both species. The animals were positioned in a
lateral prone gesture, and a longitudinal incision was made
between the left eye and ipsilateral ear.The scalpwas retracted
away from the zygomatic arch. The temporal muscle was cut
vertically and retracted to expose the lateral frontotemporal
bone at the level of the anteromedial skull base. A lateral
frontotemporal craniotomy, approximately 3 cm in diameter,
wasmade using a trephine and a craniotome in order to reach
the anterior and middle skull base (Figure 2).
The dura was opened and basal cisterns were exposed
under the operating microscope. In the pigs, one placebo
implant, which contained 25mg glucose, or one nimodip-
ine implant, which contained 5mg nimodipine, was placed
towards the scull base in the basal cisterns. One placebo
implant with glucose was placed into the brain parenchyma
in the temporal lobe in the Placebo and active groups. Among
the dogs, group Active 1 was treated with five implants
containing 8.5mg of nimodipine and group Active 2 with
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Figure 2: 3D computed tomography reconstruction indicating the
location of craniotomy and incision of the dog.
one implant containing 8.5mg of nimodipine. For both pig
and dog study, a sham group was included, where exactly
the same procedure was performed including opening the
arachnoid membrane and visualization of the optic chiasm
but no implant was placed. In all groups, dura was closed
using artificial graft (TachoSil, Baxter, USA, Deerfield, IL
60015-4625) and fibrin tissue glue (TISSEEL, Baxter, USA,
Deerfield, IL 60015-4625). The soft tissues and wound were
closed in layers. After the surgery, viability of the animals was
recorded at least twice a day. During the recovery period of 7
days for pigs and 21 days for dogs, the animals were observed
daily. Body weight and food and water consumption were
recorded once a day. Clinical signs and rectal temperature
were recorded at least twice a day.
2.6. Sampling for Nimodipine Concentration Measurements.
Plasma and CSF samples were collected for determining
nimodipine concentration. Schedules for the sampling are
presented for the pigs in Table 1 and for the dogs in Table 2,
respectively. Blood samples were collected from the external
jugular vein into K2-EDTA tubes. In pigs, samples were
collected also from ear vein. CSF samples were collected
from cisterna magna through the atlantooccipital space.
The samples were centrifuged (1200G, 10min, RT) and
plasma was separated. CSF samples were centrifuged as well
and supernatant was collected. Since nimodipine is very
photosensitive, all samples were handled with minimal light
exposure. The samples were stored frozen at −80∘C nominal
until transferred for analysis.
Liquid chromatography mass spectrometric (LC-MS)
method was used for determination of nimodipine in dog
and pig plasma and CSF samples. Sample preparation was
performed by liquid-liquid extraction. The extracts were
analyzed using reverse-phase chromatography followed by
mass spectrometry. Lower limit of quantification (LLOQ) of
the method was 0.01 ng/mL for both sample matrices.
2.7. Computed Tomography. The schedule for CT imaging is
shown in Table 1 for pigs and Table 2 for dogs. CT studies
were performed with Discovery STE PET/CT scanner (Gen-
eral Electric Medical Systems, Milwaukee, WI, USA) oper-
ated in a helical mode. Cerebral CT imaging was performed
using an ultrafast CT protocol (335mA, 100 kVp). Voxel size
was 0,625mm × 0,625mm × 0,625mm.The volume of inter-
est (VOI) was drawn for the implant(s). A calibration phan-
tom (13002 Model 3 CT Calibration Phantom, Mindways
Software, Inc, San Francisco, CA, United States) was used
prior to CT imaging and densities of the implants were calcu-
lated and corrected using the phantom data. CT image anal-
ysis was done with Carimas 2.5 software (Turku PET Cen-
tre, Turku, Finland; http://www.turkupetcentre.fi/carimas/).
Density and volume of the implant were defined using
cerebral CT imaging and implant degradation was evaluated.
Implant degradationwas calculated as a change in density and
volume of the implant at different time points (for pigs: day 1
and day 7, for dogs: days 7, 14, and 21).
2.8. Pathologic Examination. At the end of the study period,
the pigs were sedated with midazolam 1mg/kg i.m. and
xylazine 3mg/kg i.m. and euthanized with propofol i.v. over-
dose and exsanguinated. Dogs were sedated with dexmedeto-
midine 20 𝜇g/kg i.v. and euthanized with pentobarbital i.v.
overdose and exsanguinated.
The cranium of the animals was opened to expose the
operation site. Meninges and brain tissue were observed
for any macroscopic changes and the presence of implants
was evaluated. For the histopathologic examination, samples
from the meninges and brain tissue were taken from the
vicinity of the implant site and from corresponding area
on the opposite hemisphere. All samples were fixed in a
buffered 4% formaldehyde solution. The tissue samples were
embedded in paraffin, cut to a thickness of approximately
4 𝜇m, and stained with hematoxylin and eosin (HE) for
histopathology. All slides were examined by a pathologist and
histopathologic changes were recorded and scored with a 5-
step scale (from minimal to severe).
2.9. Statistical Analyses. All the results are presented asmeans
± SD. Mixed model for repeated measurements was applied
to the implant volume and density data (SAS 9.2 SAS Institute
Inc., Cary, NC, USA). 𝑃 values < 0.05 were considered as
statistically significant.
3. Results
3.1. Dissolution of the Implant In Vitro. Degradation rates of
the silica implant formulation weremeasured from three par-
allel samples.The implant formulations were totally degraded
after 3.5–4 days in in sink dissolution (Figures 3 and 4) and
24 days in flow-through dissolution, respectively (Figure 5).
The cumulative release profiles of nimodipine weremeasured
from the same sample solutions (pH = 7.4 at 37∘C) as used
for the SiO
2
degradations measurements. Nimodipine was
mainly released from the implant formulations by degrada-
tion of silica matrices as shown in Figures 3–5. The release
rates of nimodipine are proportional to the SiO
2
degradation.
According to dissolution results, therewere 5.0mg and 8.5mg
of nimodipine in implant A and implant B, respectively.
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Figure 3: Cumulative degradation of silica (◼) and release of nimo-
dipine (e) from implant A to dissolution medium (50mM Tris
buffer, pH = 7.4 at 37∘C) in in sink dissolution.
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Figure 4: Cumulative degradation of silica (◼) and release of nimo-
dipine (e) from implant B to dissolution medium (50mM Tris
buffer, pH = 7.4 at 37∘C) in in sink dissolution.
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Figure 5: Cumulative degradation of silica (◼) and release of nimo-
dipine (e) from implant B dissolution medium (50mM Tris buffer,
pH = 7.4 at 37∘C) in flow-through dissolution. Flow rate of the
dissolution medium was 500mL/day.
3.2. Surgery and Recovery Period. During the surgery, heart
rate, oxygen saturation, and rectal temperature were within
the normal range, except for one dog (number 3), which
suffered from a decrease in oxygen saturation (down to 70%).
This persisted for three minutes at the end of the operation
due to a malfunction of the ventilator. Postoperatively signs
of systemic infection were not manifested and rectal temper-
atures were within a normal range throughout the recovery
period. All clinical findings of the dogs during the 21-day
recovery period are presented in Table 3. During the 7-day
recovery period in pigs, no clinical signs of morbidity or
changed behavior were noted. Body weights of the dogs were
slightly decreased in each group: on average, in group Active
1, a decrease of 7% (𝑛 = 2) was seen, in Active 2, a decrease
of 4% was seen, and, in the sham group, a decrease of 2% was
noted. Food consumption in all dog groups remained normal
during the 21-day recovery period. In pigs, body weight gain
was 7%–18% and can be considered normal in each group,
respectively.
Mortality of this nonclinical experiment was one animal.
Animal number 3 (dog) developed refractory complex partial
epilepsy and had to be euthanized on day 3. Another dog
from the same group (number 2) had epileptic seizures
on day 4 and was treated with phenobarbital medication.
The dog responded well to the treatment. Postoperative
eye infections were treated with local ophthalmic ointment
containing fusidic acid and the infections responded well to
the treatment.
3.3. Pathological Examination. In the macroscopic exami-
nation of the pigs, no abnormalities were detected at the
implantation area. In dogs, local attachment of meninges to
the implant site was seen, which prevented the evaluation
of the actual implants. This lesion was not seen in the sham
group.
Summary of the histopathological examination is shown
in Table 4. Dog number 3 (Active 1) was sacrificed on day
3 and therefore excluded from these results. In histopatho-
logical examination of the operation site, local inflammatory
reaction characterized by infiltration of mononuclear and
granulocytic cells was seen in the meninges of both species.
In pigs, there was an eosinophilic component whereas, in
dogs, the inflammation was more neutrophilic. Multinu-
cleated giant cells indicating foreign body reaction and
foreign implant material were seen mainly in dogs receiving
five implants. Additional findings were mild to moderate
fibrosis, vascular regeneration, and mild hemorrhage on the
meninges in all groups. In general, the changes were more
frequent and severe in the dogs, but no clear differences
in the severity of changes could be seen between sham
groups and implanted groups. Furthermore, there were no
histopathological differences between the two implant types
(glucose versus nimodipine as active ingredient). In all
groups, the underlying brain parenchyma was only mildly
affected by perivascular mononuclear cuffing or spreading
of inflammatory infiltrate from the meninges. In the dog
sham group and in the Active 1 group, one animal in each
group showed focal degeneration and gliosis in the deeper
parenchyma with no direct connection to implant site. No
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Table 3: Clinical signs of the dogs during the 21-day recovery period.
Group Dog number Epileptic seizure Other/notice
Active 1
1 No —
2 Yes
Epileptiformic seizure on day 4. Treated with phenobarbital medication
2.5mg/kg twice a day on days 4–12. The medication was reduced to
2.5mg/kg once a day on day 13 and ended on day 20.
3 Yes
Epileptiformic seizure 6 hours postoperatively. Epileptiformic seizures were
refractory to phenobarbital medication. The animal had to be euthanized
on day 3 according to the protocol. It was not replaced.
Active 2
4 No 24 h postoperatively, conjunctivitis.
5 No 24 h postoperatively, vomiting.
6 No 24 h postoperatively, conjunctivitis.
Sham
7 No —
8 No 24 h postoperatively, conjunctivitis.
9 No —
Table 4: Summary of histopathological findings and severity in pigs and dogs in each group. The number of affected animals in each group
is shown. Severity score indicates the recorded minimum and maximum severity in each group. Only one score is shown if all animals had
same severity or only one animal was affected.𝑁 = 3 in each group.
Lesion Pigs Dogs
Sham Placebo Active Sham Active 1∗ Active 2
Infiltration of mononuclear cells (meninges) 1 3 3 3 2 3
Severity score, min/max∧ ++++ ++/+++ +/++++ ++++ ++++ +++/++++
Infiltration of granulocytes (meninges) 1 1 1 3 2 3
Severity score, min/max ++++ + ++ +/+++ +++ +/++
Multinucleated giant cells and foreign material (meninges) 0 0 0 0 2 1
Severity score, min/max — — — — ++ ++
Fibrosis (meninges) 1 3 1 3 2 3
Severity score, min/max ++ + ++ ++/+++ +++/++++ ++/++++
Vascular regeneration (meninges) 0 2 0 3 1 3
Severity score, min/max — +++ — ++ ++ ++
Hemorrhage +/− hemosiderophages (meninges) 1 2 1 2 1 3
Severity score, min/max + +/+++ ++++ ++ ++ ++
Perivascular cuffing (parenchyma) 0 0 1 3 2 3
Severity score, min/max — — + +/+++ ++ +/++
∗In this group, 𝑛 = 2. Animal number 3 was excluded due to preterminal sacrifice.
∧+: minimal, ++: slight, +++: moderate, ++++: marked, and —: not present.
significant abnormalities were observed in the samples from
opposite hemisphere.
The implant site located in the brain parenchyma was
present in the samples from two pigs (numbers 23D and
23F). The local changes around the parenchymal implant site
did not show major signs of foreign body reactions. There
was local inflammatory reaction with foamy macrophages
and minimal to marked degeneration in the surrounding
parenchyma, but not more than that could be expected from
the procedure itself and intraparenchymal implantation.
3.4. Nimodipine Concentrations. In pigs, calculated CSF/
peripheral venous plasma ratio was 1.31 ± 1.34 on day 5 and
0.886 ± 0.255 on day 7. Correspondingly in dogs receiving
active implant, after one hour in 5× 8,5mgnimodipine group,
the CSF/jugular plasma ratio was 0.002 ± 0.0005 and in
8,5mg nimodipine group 0.149 ± 0.174.The sustained release
profile of nimodipine in CSF was achieved for 21 days in dogs
and 7 days in pigs (Table 5).
3.5. Computed Tomography Imaging. Clinical analyses of the
CT data showed the location and degradation of the implants
in the subarachnoid space in pigs and dogs. The implants
were correctly placed at the base of the cranium in the
Sylvian fissure in the subarachnoid space in all pigs. This
was also noted in most dogs, except for dogs number 2 and
number 3 in group Active 1 (Figure 6). Dog number 3 had
to be euthanized at day 3 and CT imaging was therefore not
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Table 5: Concentrations of nimodipine at different time points after surgery in dogs and pigs (ng/mL).
1 h Day 7 Day 14 Day 21
Jugularis CSF Jugularis CSF Jugularis CSF Jugularis CSF
Nimodipine 8.5mg
implant in dogs 17.79 ± 15.17 2.19 ± 1.90 6.13 ± 4.66 0.025 ± 0.009 11.51 ± 3.77 0.030 ± 0.008 3.05 ± 1.53 0.013 ± 0.004
Nimodipine 5 × 8.5mg
implant in dogs 63.9 ± 18.7 0.110 ± 0.005 37.8 ± 15.8 0.095 ± 0.008 36.5 ± 9.97 0.083 ± 0.009 32.9 ± 8.77 0.034 ± 0.004
Day 5 Day 7
Jugularis Ear CSF Jugularis Ear CSF
Nimodipine 5mg
implant in pigs 0.045 ± 0.008 0.027 ± 0.005 0.027 ± 0.022 0.054 ± 0.006 0.045 ± 0.020 0.038 ± 0.017
10mm
(a) (b)
Figure 6: Coronal CT scanning of the dogs number 1 (A) and number 2 (B) one week postoperatively. (a) Five implants in the basal cisterns
(thick arrow), no clinical signs of intolerance observed. Craniotomy site is indicated by thin arrow. (b) Scanning indicates a too rostral
positioning of the implants, and five implants had formed pile-like formation protruding into the parenchyma of the frontal lobe (thick
arrow). Craniotomy site is indicated by thin arrow.
performed. CT imaging of dog number 2 showed a too rostral
positioning of the implants, and five implants had formed
pile-like formation protruding 6,5mm into the parenchyma.
In dogs, implant size and density were decreased in
implants measured between weeks 1 and 3 (Figure 7). Degra-
dation was very linear. Based on slopes of the degradation
curves, density was decreased faster than volume (Table 6).
4. Discussion
The objective to deliver nimodipine biodegradable silica-
based implants into the subarachnoid space through fron-
totemporal craniotomy in pigs and dogs wasmet.The surgery
and the recovery period of the pigs were passed without any
complications. In the dogs, two animals developed epileptic
seizures, both receiving five 8,5mg nimodipine implants
into the basal cisterns. One had to be euthanized due
to refractory epileptic seizures, the second responded well
to the phenobarbital treatment, and the medication could
be terminated by day 20. Refractory epilepsy of the dog
number 3was probably caused by the combination of hypoxia
during surgery and mild protrusion of the implants into the
parenchyma that was observed in autopsy. In theCT imaging,
dog number 2 showed improper placement of implants
and protrusion of the implants into parenchyma, which
may have caused the seizures. This dog showed also focal
parenchymal degeneration in the histopathology, which may
have been related to the protrusion of implants. Although the
evidence is suggesting direct compression of the frontal lobe
parenchyma to be behind the seizures, in theory, it is possible
that the etiology may rise from the surgery itself or as a direct
adverse effect of the implants.
In the beginning of the study, five implants were deter-
mined to be the number of implants for testing toxicity levels
of the nimodipine silica-implant. This number of implants
was also the maximum that could be delivered into the basal
cisterns of a beagle dog. In histopathological examination
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Figure 7: Implant volume and density curves for dogs. HU =
Hounsfield Unit.
Table 6: Statistical parameters of implant volume and density data
for dogs. Implant density is decreasing faster based on slope of the
degradation curves.
Intercept Slope 𝑃 value
Volume 148.12 −1.7829 0.0442
Density 402.93 −5.4000 0.0002
of dogs and pigs, no major differences were noted between
groups regardless of the presence of implants and most of
the findings were present also in the sham-operated animals,
indicating that these findings were related to the procedure
itself and that the implants are locally tolerable. Foreign
body type reaction was mainly seen in dogs receiving five
implants, which can be directly related to the larger amount of
implant material. Additionally, the implantation directly into
the brain parenchyma of pigs did not produce widespread
tissue damage around the implant. Therefore silica-based
biodegradable materials can be considered for use in the
release of the therapeutic agents for an intracranial treatment
of vasospasm and DCI.
Based on the nimodipine concentrations in the CSF,
sustained release profile of nimodipine was achieved for
21 days in dogs and 7 days in pigs. Interestingly, despite
the intracisternal location of the implants, the increase of
nimodipine concentration in CSF was modest. The samples
were taken through atlantooccipital space from cisterna
magna and therefore the low concentrations could be due to a
net flow of CSF towards arachnoid villi and sinuses, resulting
in a lower concentration in CSF located extracranially or
cisterna magna. There might be some specific features in
implant or nimodipine amount that leads to lower CSF con-
centrations. For example, Cook et al. reported significantly
lower nimodipine concentration in CSF when using 30mg
loaded nimodipine PLGA microparticles compared to the
10mg loaded PLGAmicroparticles [15]. Indeed, the SAH and
also the neurosurgical procedure itself may compromise the
normal CSF dynamics. Sufficient CSF dynamics are required
for the implant dissolution and distribution of nimodipine.
Thus pharmacokinetics and the degradation of the implants
after SAH need to be studied in further trials.
The physical degradation of the silica implant and pre-
diction of the implant behavior in vivowere feasible to follow
using CT imaging. High dissolution rates in the basal cisterns
may be induced by increased circulation of spinal fluid. A
rapid decrease of the density is in line with the physical
properties of the implant matrix. The degradation of silica
matrix occurs constantly throughout the implant; therefore,
the implant size decreases slower than its density. Based on
the results obtained in this study, CT imaging can be a feasible
method for determination of the degradation of the silica
implants in vivo. More studies are needed to clarify if CT
imaging can be used to estimate the drug release profile of
silica implants.
5. Conclusions
In conclusion, we found that a biodegradable silica-based
implant can be used as a material for an intracranial drug
delivery system and no major histopathological foreign body
reactions were observed. A sustained release profile of the
nimodipine implant was achieved and compared to the
traditional treatment; higher nimodipine CSF/Plasma ratios
may be obtained. CT imaging proved to be a feasible method
for observing the in vivo degradation properties of a silica-
based implant. More studies are needed to understand the
pharmacokinetics of the intracranial nimodipine delivery
systems, and further formulation development of the implant
to a sustained drug release gel may be of interest from a
clinical point of view.
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